Stéphane Dalle
Université Claude Bernard Lyon 1(FR)Centre National de la Recherche Scientifique(FR)Centre National de la Recherche Scientifique(FR)Inserm(FR)Inserm(FR)Lyon College(US)Hospices Civils de Lyon(FR)Hospices Civils de Lyon(FR)Centre Léon Bérard(FR)Hôpital Lyon Sud(FR)Hôpital Nord(FR)Centre de Recherche en Cancérologie de Lyon(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Cutaneous lymphoproliferative disorders research, Melanoma and MAPK Pathways
Most-Cited Works
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma(2018)1,816 cited
- → Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study(2019)915 cited
- → Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial(2018)630 cited
- → Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial(2017)569 cited
- → A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma(2011)